18F-deoxyglucose PET: Useful in the management of patients with stem cell transplantation for lymphoma?

Expert Review of Hematology

Volumn 3, Issue 4, 2010, Pages 405-410

  Kletter, Kurt ^a   Kalhs, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

18F deoxyglucose positron emission tomography; allogeneic; autologous; follow up; lymphoma; prognostic value; stem cell transplantation

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FOLLOW UP; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REDUCED INTENSITY CONDITIONING; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 77955596704     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.10.35     Document Type: Article

References (25)

1. Elstrom R, Guan L, Baker G et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101(10), 3875-3876 (2003).
2. Paes FM, Kalkanis DG, Sideras PA, Serafini AN. FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. Radiographics 30(1), 269-291 (2010).
3. Schöder H, Noy A, Gönen M et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkins lymphoma. J. Clin. Oncol. 23, 4643-4651 (2005).
4. Bruzzi JF, Macapinlac H, Tsimberidou AM et al. Detection of Richters transformation of chronic lymphocytic leukemia by PET/CT. J. Nucl. Med. 47, 8 (2006).
5. Noy A, Schoder H, Gonen M et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann. Oncol. 20(3), 508-512 (2009).
6. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood 110(10), 3507-3516 (2007).
7. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 25(5), 579-586 (2007).
8. Juweid ME, Stroobants S, Hoekstra OS et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J. Clin. Oncol. 25(5), 571-578 (2007).
9. Delbeke D, Stroobants S, de Kerviler E, Gisselbrecht C, Meignan M, Conti PS. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. Oncologist 14(Suppl. 2), 30-40 (2009).
10. Schöder H, Moskowitz C. PET imaging for response assessment in lymphoma: potential and limitations. Radiol. Clin. North Am. 46(2), 225-241 (2008).
11. Robinson SP, Goldstone AH, Mackinnon S et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100(13), 4310-4316 (2002).
12. Johnston PB, Wiseman GA, Micallef IN. Positron emission tomography using F18 fluorodeoxyglucose pre and post-autologous stem cell transplant in non-Hodgkins lymphoma. Bone Marrow Transplant. 41(11), 919-925 (2008).
13. Schot BW, Zijlstra JM, Sluiter WJ et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 109(2), 486-491 (2007).
14. Poulou LS, Thanos L, Ziakas PD. Unifying the predictive value of pretransplant FDG PET in patients with lymphoma: a review and meta-analysis of published trials. Eur. J. Nucl. Med. Mol. Imaging 37(1), 156-162 (2010).
15. Lambert JR, Bomanji JB, Peggs KS et al. Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. Blood 115(14), 2763-2768 (2010).
16. Spaepen K, Stroobants S, Dupont P et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 102(1), 53-59 (2003).
17. Yoshimi A, Izutsu K, Takahashi M et al. Conventional allogeneic hematopoietic stem cell transplantation for lymphoma may overcome the poor prognosis associated with a positive FDG-PET scan before transplantation. Am. J. Hematol. 83(6), 477-481(2008).
18. Gisselbrecht C, Vose J, Nademanee A, Gianni AM, Nagler A. Radioimmunotherapy for stem cell transplantation in non-Hodgkins lymphoma: in pursuit of a complete response. Oncologist 14(Suppl. 2), 41-51 (2009).
19. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77 (3), 649-653 (1991).
20. Mandigers CM, Verdonck LF, Meijerink JP, Dekker AW, Schattenberg AV, Raemaekers JM. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant. 32(12), 1159-1163 (2003).
21. Russell NH, Byrne JL, Faulkner RD, Gilyead M, Das-Gupta EP, Haynes AP. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant. 36(5), 437-441 (2005).
22. Weiler-Sagie M, Bushelev O, Epelbaum R et al. 18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J. Nucl. Med. 51(1), 25-30 (2010).
23. Hart DP, Avivi I, Thomson KJ et al. Use of 18F-FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions. Br. J. Haematol. 128(6), 824-829 (2005).
24. Mendler JH, Friedberg JW. Salvage therapy in Hodgkins lymphoma. Oncologist 14(4), 425-432 (2009).
25. Bishop MR, Dean RM, Steinberg SM et al. Correlation of pretransplant and early posttransplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkins lymphoma. Cancer 116(4), 852-862 (2010).